Clinical trials
Antiphospholipid Syndrome clinical trials
Below are recruiting antiphospholipid syndrome clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07142239Recruiting
Blood markers in primary vs. secondary antiphospholipid syndrome
This study looks at three blood markers (MPV, PLR, and NLR) in people with antiphospholipid syndrome (APS) to see if they differ between primary APS (no other autoimmune disease) and secondary APS (with lupus or another autoimmune condition). It may help doctors better understand and manage APS.
Al Khārjah, Kharga OasisAges 18 years+ - NCT06373003Recruiting
Studying antiphospholipid syndrome without antibodies
This trial looks at people who have symptoms of antiphospholipid syndrome (APS) but test negative for the usual antibodies. It will compare these patients to those with positive antibody tests to better understand the condition and improve diagnosis and treatment.
Roma, RomeAges 18–65 - NCT06373926Recruiting
Blood test for Annexin A2 in antiphospholipid syndrome
This study tests how a blood sample can help doctors better understand Antiphospholipid Syndrome (APS) by measuring a protein called Annexin A2 on white blood cells. It may lead to easier diagnosis and monitoring of this condition.
AmiensAges 18 years+ - NCT07178925Recruiting
Long-term study of antiphospholipid syndrome
This trial follows patients with antiphospholipid syndrome over time to learn more about the condition. It may help researchers understand how the disease progresses and how to better manage it.
RouenAges 18–75 - NCT05583305Enrolling by invitation
Study brain artery narrowing causes in adults with antiphospholipid syndrome
This study looks at how often the brain’s arteries become narrowed in people with antiphospholipid syndrome (APS), and why it happens. It may help you and doctors better understand the cause and how to detect it early using a brain MRI scan.
Hong KongAges 18 years+ - NCT00482794Recruiting
Study genetic risk factors for antiphospholipid antibody syndrome
This study looks at genetic (inherited) risk factors in people who have antiphospholipid antibodies and related symptoms. Your results may help researchers better predict who is at risk and improve care for antiphospholipid antibody syndrome.
Durham, North CarolinaAges Any age - NCT07584083RecruitingPhase 2
Anifrolumab for Primary Antiphospholipid Syndrome
This trial tests a new drug called anifrolumab in adults with primary antiphospholipid syndrome (a blood clotting disorder). The drug may help reduce clotting and related complications by working with your immune system.
Athens, GreeceAges 18–70 - NCT05199909RecruitingPhase 2
Testing zanubrutinib for antiphospholipid syndrome with low platelets
This Phase 2 study tests zanubrutinib, a medicine for the immune system, to treat antiphospholipid syndrome when it causes very low platelet counts. It looks at safety and whether it can improve blood clotting problems and low platelets when prior steroid treatment didn’t work well.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05995600RecruitingPhase 4
Clopidogrel vs warfarin to prevent a second APS stroke
This study compares two types of blood thinners — clopidogrel (an antiplatelet) and warfarin — to prevent another stroke in people with antiphospholipid syndrome (APS). It aims to find which medicine works better for people who have already had a stroke related to APS.
AnyangAges 19 years+ - NCT07757789Recruiting
Platelet changes in antiphospholipid syndrome
This study looks at how platelet counts change over time in people with antiphospholipid syndrome (APS), a condition that can cause blood clots and pregnancy problems. It may help doctors better understand and manage low platelets in APS patients.
Al Khārjah, Kharga OasisAges 18 years+ - NCT00198068Recruiting
Study pregnancy outcomes in lupus and antiphospholipid syndrome
This study looks for factors that may predict how pregnancy turns out in people with lupus (SLE) and/or antiphospholipid syndrome (APS). It may help doctors better understand what to monitor in early pregnancy to support healthier outcomes.
Chicago, IllinoisAges 18–45 - NCT05786235Recruiting
Pregnant people with or without antiphospholipid antibodies
This study is looking at pregnancy outcomes in people who are pregnant and either have antiphospholipid antibody syndrome (APS) or do not have APS but do have prior full-term pregnancies. It may help doctors understand risks and how to manage pregnancies in these groups.
MilanAges 18–45 - NCT00616317Recruiting
Study for children with antiphospholipid syndrome and blood clots
This study is for children who have antiphospholipid syndrome (APS) and a history of blood vessel clots. Researchers want to learn more about APS in pediatric patients who have specific blood test signs and clot history.
Sacramento, CaliforniaAges 1 minute–18 years - NCT07163338Recruiting
Antiphospholipid syndrome in older stroke patients
This study looks for a blood clotting disorder called antiphospholipid syndrome (APS) in people aged 65 and older who have had a stroke or a mini-stroke (TIA). The goal is to understand how common APS is in this group and if it affects recovery.
ReimsAges 65 years+ - NCT05679206Recruiting
Postpartum care study for pregnancy blood-pressure complications
This study looks at people with preeclampsia during pregnancy and how their lung blood pressure and related symptoms change after delivery. It may help doctors better monitor and manage postpartum risks, especially involving the heart and lungs.
BernAges 16 years+ - NCT06614270Recruiting
CAR-NK cell therapy for severe autoimmune diseases
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
Hangzhou, ZhejiangAges 18–65 - NCT04308564Recruiting
Study of lab and clinic data in antiphospholipid patients
This study looks at lab results and clinic information in people who have antiphospholipid antibodies. The goal is to better understand these antibody-positive conditions and what happens over time, which may help improve care.
LilleAges 18 years+ - NCT07743242Recruiting
Study of hemolytic anemia in antiphospholipid syndrome
This study looks at how autoimmune hemolytic anemia (when the body attacks its own red blood cells) relates to antiphospholipid syndrome (a condition that increases blood clot risk). It aims to better understand this connection, which may help improve care for people with both conditions.
Al Khārjah, Kharga OasisAges 18 years+ - NCT06379646Recruiting
YTS109 cell therapy for autoimmune disease
This study tests a new cell therapy (YTS109) for people with autoimmune diseases like lupus or Sjogren's syndrome that have not improved or keep coming back after standard treatments. It aims to see if the treatment can help control the disease.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT05230017Recruiting
Study to follow people with antiphospholipid antibodies
This study looks at people who test positive for antiphospholipid antibodies on more than one blood test. It helps researchers better understand the condition and how to follow patients over time.
Beijing, Beijing MunicipalityAges Any age - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80 - NCT06371417RecruitingPhase 1
Testing RAY121 for several immune diseases (RAINBOW trial)
This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.
Orange, CaliforniaAges 18–85 - NCT06723106Enrolling by invitationPhase 1
Long-term safety study of RAY121 for immune conditions
This study is for people who already took RAY121 in a previous trial and did well. It tests whether continuing the treatment is safe and effective over a longer period. The goal is to manage chronic immune conditions.
Camperdown, New South WalesAges 18–85 - NCT05904301Recruiting
Registry for autoimmune and autoinflammatory disease patients
This study builds a nationwide list (registry) of people with certain autoimmune or inflammation-related illnesses. It helps researchers understand these diseases better over time, which can guide future care.
YerevanAges Any age
Hear when a new Antiphospholipid Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antiphospholipid syndrome?
- Yes. Clin2 currently lists 42 recruiting antiphospholipid syndrome studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antiphospholipid syndrome trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antiphospholipid syndrome trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.